香港股市 已收市

歸創通橋-B (2190.HK)

HKSE - HKSE 延遲價格。貨幣為 HKD。
加入追蹤清單
9.6900.000 (0.00%)
收市:04:08PM HKT

歸創通橋-B

Zylox-Tonbridge Industrial Park
No. 270 Shuyun Road Cangqian Street Yuhang District
Hangzhou
China
86 571 8861 0082
https://www.zyloxtb.com

版塊Healthcare
行業Medical Devices
全職員工765

高階主管

名稱頭銜支付行使價出生年份
Dr. Zhong ZhaoFounder, Chairman & CEO6.5M1968
Mr. Yang XieSenior VP of Sales & Marketing and Executive Director3.68M1970
Dr. Zheng LiSenior VP, GM of Neurovascular Business & Executive Director11.17M1978
Mr. Quanwei YuanCFO & Joint Company Secretary1980
Ms. Sau In KwanJoint Company Secretary
截止 2022年12月31日為止計算的金額,現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 HKD。

描述

Zylox-Tonbridge Medical Technology Co., Ltd., a medical device company, provides neuro- and peripheral-vascular interventional medical devices the People's Republic of China and internationally. The company develops neurovascular product portfolio that covers a suite of products for various categories, including ischemic stroke, hemorrhagic stroke, intracranial stenosis, carotid artery, and intracranial access devices. It also develops peripheral-vascular interventional product portfolio covering a spectrum of arterial and venous products comprising stents, balloons, catheters, and filters, as well as covers hemodialysis access, aortic intervention, peripheral embolization intervention, and radiological intervention products. In addition, the company provides technical consultation and services; as well as imports materials. The company was formerly known as Zhejiang Zylox Medical Device Co., Ltd. and changed its name to Zylox-Tonbridge Medical Technology Co., Ltd. in March 2021. Zylox-Tonbridge Medical Technology Co., Ltd. was incorporated in 2012 and is headquartered in Hangzhou, the People's Republic of China.

公司管治

截至 無 止,歸創通橋-B 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中:無;董事會:無;股東權利:無;現金賠償:無。

企業管治評分的資料提供: Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險,而 10 分表示較高的管治風險。